The faster we appear to be moving in discovery, it seems, the more pronounced the gap between technology advances and product commercialization. When we get back to earth-bound reality, new products aren't getting to the market any faster than they used to, and the speed of physician adoption appears to be a constant. The idea plays out in drug development, where we have to take the time to study the effect of a drug candidate in man before we can determine what clinical questions researchers should ask, much less what the answers are. It will also play out in personalized medicine: We're still not to the point where the first SNP panel has made its way into a pivotal trial, much less to regulatory agencies, physicians, or patient/consumers. That means the debate about the social or ethical ramifications of collecting and using pharmacogenomic information, and an understanding of the basis for the forces that will push against rapid adoption are premature. In a manner of speaking, we haven't even gotten to the stage of testing our responses in patieants.
You may also be interested in...
Having kept out of the race to develop a vaccine, Novartis has joined efforts with a collaboration using the AAV gene therapy vector.
Philips has added a Clinical Trials Accelerator functionality to the cloud-based HealthSuite digital platform, underlining its role in securely managing and collecting device and personal data for use by third-party clients seeking to build health care solutions.
Bavencio’s Survival Benefit Confirmed In Front-Line Maintenance Therapy For Advanced Urothelial Cancer
Further details of Merck KGaA/Pfizer-funded JAVELIN Bladder 100 study presented at this year’s ASCO confirm avelumab’s survival benefit when used as front-line maintenance therapy in patients with advanced urothelial cancer that has not progressed following initial chemotherapy.